{"transactions":[{"id":675908,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-08-25T20:43:22.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":29697,"price":2.12,"value":62957.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects forfeiture of 54,479 shares subject to performance RSUs granted to the Reporting Person on August 14, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 7,495 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program."}],"balance_after":488267,"source":{"system":"sec-edgar","filing":"0001628280-26-058920","document":"wk-form4_1787690594.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000162828026058920/wk-form4_1787690594.xml","form_type":"4"}},{"id":919169,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Restricted Stock Unit","published_at":"2026-02-04T22:12:18.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":152480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."}],"balance_after":152480,"derivative":{"underlying":"Common Stock","underlying_shares":152480},"source":{"system":"sec-edgar","filing":"0001362155-26-000002","document":"wk-form4_1770243135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000136215526000002/wk-form4_1770243135.xml","form_type":"4"}},{"id":919168,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-04T22:12:18.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":539072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":539072,"derivative":{"exercise_price":1.87,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":539072},"source":{"system":"sec-edgar","filing":"0001362155-26-000002","document":"wk-form4_1770243135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000136215526000002/wk-form4_1770243135.xml","form_type":"4"}},{"id":919167,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-02-04T22:12:18.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":22900,"price":1.76,"value":40304.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.82, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":564948,"source":{"system":"sec-edgar","filing":"0001362155-26-000002","document":"wk-form4_1770243135.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000136215526000002/wk-form4_1770243135.xml","form_type":"4"}},{"id":1281598,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-02-05T21:16:37.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":6404,"price":1.71,"value":10950.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":587848,"source":{"system":"sec-edgar","filing":"0001737287-25-000020","document":"wk-form4_1738790190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000173728725000020/wk-form4_1738790190.xml","form_type":"4"}},{"id":1292871,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Stock Option (Right to buy)","published_at":"2025-01-29T01:16:11.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":512370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":512370,"derivative":{"exercise_price":1.94,"expiration_date":"2035-01-24","underlying":"Common Stock","underlying_shares":512370},"source":{"system":"sec-edgar","filing":"0001737287-25-000009","document":"wk-form4_1738113364.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000173728725000009/wk-form4_1738113364.xml","form_type":"4"}},{"id":1292870,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-01-29T01:16:11.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":144928,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":594252,"source":{"system":"sec-edgar","filing":"0001737287-25-000009","document":"wk-form4_1738113364.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000173728725000009/wk-form4_1738113364.xml","form_type":"4"}},{"id":1424068,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"officer":true,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2024-08-23T20:15:09.000Z","date":"2024-08-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":28310,"price":2.785,"value":78843.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":449324,"source":{"system":"sec-edgar","filing":"0001593968-24-001096","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000159396824001096/primary_01.xml","form_type":"4"}},{"id":1664927,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"officer":true,"officer_title":"SVP, General Counsel"}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-31T22:48:49.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":147778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter."}],"balance_after":147778,"derivative":{"exercise_price":3.2,"expiration_date":"2034-01-25","underlying":"Common Stock","underlying_shares":147778},"source":{"system":"sec-edgar","filing":"0001593968-24-000196","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000159396824000196/primary_01.xml","form_type":"4"}},{"id":1664926,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"officer":true,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2024-01-31T22:48:49.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":41800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":477634,"source":{"system":"sec-edgar","filing":"0001593968-24-000196","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000159396824000196/primary_01.xml","form_type":"4"}},{"id":1803131,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"officer":true,"officer_title":"GENERAL COUNSEL"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-17T22:57:35.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":960854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the stock option shall vest on August 14, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":960854,"derivative":{"exercise_price":4.13,"expiration_date":"2033-08-14","underlying":"Common Stock","underlying_shares":960854},"source":{"system":"sec-edgar","filing":"0001593968-23-001226","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000159396823001226/primary_01.xml","form_type":"4"}},{"id":1803130,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"officer":true,"officer_title":"GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2023-08-17T22:57:35.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":326876,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":435834,"source":{"system":"sec-edgar","filing":"0001593968-23-001226","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000159396823001226/primary_01.xml","form_type":"4"}},{"id":1803129,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"officer":true,"officer_title":"GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2023-08-17T22:57:35.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":108958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitutes Performance Restricted Stock Units (\"PRSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each PRSU upon vesting,  50% shall vest in the event the Company achieves a 30-day weighted average share price of $18 on or before March 22, 2026 and 50% shall vest upon the first marketing approval of a Company product by the US FDA on or before March 22, 2028."}],"balance_after":108958,"source":{"system":"sec-edgar","filing":"0001593968-23-001226","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000159396823001226/primary_01.xml","form_type":"4"}}]}